Rocket Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RCKT Nasdaq 8731 https://www.rocketpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease - Sep 17th, 2024 11:00 am
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors - Sep 10th, 2024 11:00 am
Rocket Stock Down More Than 30% in Past Six Months: Here's Why - Sep 9th, 2024 3:02 pm
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound? - Sep 4th, 2024 3:30 pm
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Aug 27th, 2024 11:00 am
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks - Aug 25th, 2024 1:06 pm
Rocket Pharmaceuticals: Q2 Earnings Snapshot - Aug 5th, 2024 8:14 pm
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? - Aug 2nd, 2024 10:31 am
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease - Jul 1st, 2024 2:31 pm
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides - Jun 28th, 2024 1:52 pm
Rocket gene therapy rejected by FDA over manufacturing - Jun 28th, 2024 11:58 am
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) - Jun 28th, 2024 11:27 am
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? - Jun 5th, 2024 3:30 pm
Rocket Pharmaceuticals (NASDAQ:RCKT) Is In A Good Position To Deliver On Growth Plans - May 31st, 2024 10:21 am
EC grants orphan medicinal product status to Rocket’s RP-A601 - May 30th, 2024 10:35 am
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - May 29th, 2024 11:00 am
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - May 10th, 2024 10:00 am
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil - May 7th, 2024 3:26 pm
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress - May 6th, 2024 8:01 pm
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why - Apr 30th, 2024 4:00 pm